Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Healthcare Industry News How cinchona bark became the world’s first antimalarial drug and still influences modern medicine Learn how cinchona bark led to the discovery of quinine, shaped antimalarial treatment, and continues to impact cardiac therapy and global pharmacology today. bypharmanewsdailyJuly 13, 2025